• Organizations: Kodiak Sciences
Kodiak enrolls first patients in phase 3 DME study for bispecific therapy
Pipeline

Kodiak enrolls first patients in phase 3 DME study for bispecific therapy

KSI-501 advances to two registrational phase 3 trials, with topline data for wet AMD expected in Q3 2026.
Kodiak reports positive phase 3 data on tarcocimab for DR
Pipeline

Kodiak reports positive phase 3 data on tarcocimab for DR

Topline findings from the GLOW2 trial indicate Zenkuda’s superiority over sham as company plans for a multi-indication FDA filing.
Kodiak Sciences concludes enrollment for phase 3 DR on tarcocimab
Pipeline

Kodiak Sciences concludes enrollment for phase 3 DR on tarcocimab

Anti-VEGF tarcocimab tedromer is under clinical investigation as a mainstay IVT monotherapy with twice-yearly dosing for three retinal indications.
Nona Biosciences and Kodak Sciences to advance antibody therapies for ophthalmic diseases
Pipeline

Nona Biosciences and Kodak Sciences to advance antibody therapies for ophthalmic diseases

Kodiak to further develop retinal disease asserts via Nona’s Harbour Mice platform, designed to generate fully human monoclonal antibodies at half the size of regular IgG.
Kodiak is restarting its tarcocimab clinical program for three retinal disease indications
Pipeline

Kodiak is restarting its tarcocimab clinical program for three retinal disease indications

Just 3 months after discontinuing tarcocimab tedromer for DME, new phase 3 data may support an indication for diabetic retinopathy.